Telaprevir is an inhibitor of the HCV NS3/4A protease. When used in combination with pegylated interferon and ribavirin, telaprevir has demonstrated a substantial increase in sustained virological response compared with pegylated interferon and ribavirin used alone. Telaprevir has good oral bioavailability, which is enhanced when administered with food. Telaprevir is extensively metabolized and primarily eliminated via faeces. No dose adjustment of telaprevir is needed in patients with mild to severe renal impairment or mild liver impairment. Telaprevir is a substrate and inhibitor of cytochrome P450 3A and P-glycoprotein and, thus, might interact with coadministered drugs that affect or are affected by these metabolic/transport pathways. This article reviews the pharmacokinetic and drug interaction profile of telaprevir.
References
1.
WasleyA., AlterM.J.Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis2000; 20: 1–16.
2.
SimmondsP., HolmesE.C., ChaT.A.Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol1993; 74: 2391–2399.
3.
SeeffL.B.Natural history of chronic hepatitis C. Hepatology2002; 36: S35–S46.
4.
Centers for Disease Control and Prevention.Hepatitis C FAQs for health professionals. (Updated 25 April 2012. Accessed 3 October 2011.) Available from http://www.cdc.gov/hepatitis/hcv/hcvfaq.htm.
5.
MühlbergerN., SchwarzerR., LettmeierB.HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health2009; 9: 34.
6.
PerniR.B., AlmquistS.J., ByrnR.A.Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother2006; 50: 899–909.
7.
LinC., KwongA.D., PerniR.B.Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets2006; 6: 3–16.
8.
ReesinkH.W., ZeuzemS., WeeginkC.J.Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a Phase Ib, placebo-controlled, randomized study. Gastroenterology2006; 131: 997–1002.
9.
Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA.INCIVEK (telaprevir). United States Prescribing Information 2012. (Updated June 2012. Accessed 11 July 2012.) Available from http://pi.vrtx.com/files/uspi_telaprevir.pdf.
Vertex Pharmaceuticals Incorporated, Laval, QC, Canada.INCIVEK (telaprevir). Canada Product Monograph 2011. (Updated 29 June 2012. Accessed 11 July 2012.) Available from http://pi.vrtx.com/files/canadapm_telaprevir_en.pdf.
12.
JacobsonI.M., McHutchisonJ.G., DusheikoG.M.Telaprevir for previously untreated chronic hepatitis C infection. N Engl J Med2011; 364: 2405–2416.
13.
ShermanK.E., FlammS.L., AfdhalN.H.Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med2011; 365: 1014–1024.
14.
ZeuzemS., AndreoneP., PolS.Telaprevir for retreatment of HCV infection. N Engl J Med2011; 364: 2417–2428.
15.
van HeeswijkR., BoogaertsG., De PaepeE.The effect of different types of food on the bioavailability of the investigational HCV protease inhibitor telaprevir.6th International Workshop on Clinical Pharmacology of HCV Therapy. 22–24 June 2011, Cambridge, MA, USA. Abstract PK_19.
16.
ChakilamA., ChavanA., SmithG.Telaprevir binding to isolated human plasma proteins and protein binding displacement interactions between telaprevir and warfarin.6th International Workshop on Clinical Pharmacology of HCV Therapy. 22–24 June 2011, Cambridge, MA, USA. Abstract PK_20.
17.
AdiwijayaB., ChandorkarG., van HeeswijkR.Effect of mild and moderate hepatic impairment on telaprevir pharmacokinetics.6th International Workshop on Clinical Pharmacology of HCV Therapy. 22–24 June 2011, Cambridge, MA, USA. Abstract PK_1.
18.
FraeymanN.F., DelloC.D., BelpaireF.M.Alpha 1-acid glycoprotein concentration and molecular heterogeneity: relationship to oxprenolol binding in serum from healthy volunteers and patients with lung carcinoma or cirrhosis. Br J Clin Pharmacol1988; 25: 733–740.
19.
MiyazawaY., BlumR.A., SchentagJ.J.Pharmacokinetics and safety of tamsulosin in subjects with normal and impaired renal or hepatic function. Curr Ther Res Clin Exp2001; 62: 603–621.
20.
Pegasys (peginterferon alfa-2a).Package insert2011. GenentechSouth San Francisco, CA, USA.
21.
Rebetol (ribavirin USP).United States Prescribing Information2010. Merck, Whitehouse Station, NJ, CA, USA.
22.
ZhangY., ZhangL., AbrahamS.Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clin Pharmacol Ther2009; 85: 305–311.
23.
van HeeswijkR., Van de VoordeA., BoogaertsG.The effect of severe renal impairment on the pharmocokinetics of the investigational HCV protease inhibitor telaprevir. J Hepatol2011; 54Suppl 1: S492.
24.
MarcellinP., FornsX., GoeserT.Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology2011; 140: 459–468.
25.
MauriceM., PichardL., DaujatM.Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J1992; 6: 752–758.
26.
von MoltkeL.L., GreenblattD.J., GrassiJ.M.Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol1998; 38: 106–111.
27.
GargV., ChandorkarG., YangY.The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers. Br J Clin Pharmacol2012; doi: 10.1111/j.1365-2125.2012.04345.x.
28.
GargV., LuoX., McNairL.The effect of low-dose ritonavir on the pharmacokinetics of the investigational HCV protease inhibitor telaprevir in healthy volunteers.18th Conference on Retroviruses and Opportunistic Infections (CROI), 27 February–3 March 2011, Boston, MA, USA. Abstract 629.
29.
FoisyM.M., YakiwchukE.M., HughesC.A.Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother2008; 42: 1048–1059.
GargV., ChandorkarG., FarmerH., SmithF., AlvesK., van HeeswijkR.Effect of telaprevir on the pharamcokinetics of midazolam and digoxin. J Clin Pharmacol2012; doi: 10.1177/0091270011419850.
32.
StochS.A., FriedmanE., MaesA.Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm. J Clin Pharmacol2009; 49: 398–406.
33.
DumondJ.B., VourvahisM., RezkN.L.A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther2010; 87: 735–742.
34.
SchmittC., HofmannC., RiekM., PatelA., ZwanzigerE.Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe. Pharmacotherapy2009; 29: 1175–1181.
35.
Swainston HarrisonT., KeatingG.M.Zolpidem: a review of its use in the management of insomnia. CNS Drugs2005; 19: 65–89.
36.
VersterJ.C., VolkertsE.R.Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature. CNS Drug Rev2004; 10: 45–76.
37.
LuurilaH., KivistoK.T., NevonenP.J.Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem. Eur J Clin Pharmacol1998; 54: 163–166.
38.
WennerholmA., AllqvistA., SvenssonJ.O.Alprazolam as a probe for CYP3A using a single blood sample: pharmacokinetics of parent drug, and of a- and 4-hydroxy metabolites in healthy subjects. Eur J Clin Pharmacol2005; 61: 113–118.
39.
GreenblattD.J., von MoltkeL.L., HarmatzJ.S.Alprazolam-ritonavir interaction: implications for product labeling. Pharmacokinetics and drug disposition. Clin Pharmacol Ther2000; 67: 335–341.
40.
LuoX., van HeeswijkR., AlvesK., GargV.The effect of telaprevir on the pharmaokinetics of alprazolam and zolpidem in healthy volunteers.6th International Workshop on Clinical Pharmacology of HCV Therapy. 22–24 June 2011, Cambridge, MA, USA. Abstract PK_11.
41.
Caduet (amlodipine besylate/atorvastatin calcium). Package insert2006. PfizerNew York, NY, USA.
42.
JukemaJ.W., van der HoornJ.W.Amlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapy. Expert Opin Pharmacother2004; 5: 459–468.
43.
McGregorD.O., BaileyR.R., RobsonR.A.Amlodipine has a minor effect on cyclosporine metabolism. Clin Nephrol1997; 48: 336.
44.
NishioS., WatanabeH., KosugeK.Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. Hypertens Res2005; 28: 223–227.
45.
MaB., PrueksaritanontT., LinJ.H.Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos2000; 28: 125–130.
46.
HermannM., BogsrudM.P., MoldenE.Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy. Clin Pharmacol Ther2006; 79: 532–539.
47.
LeeJ.E., van HeeswijkR., AlvesK.Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin. Antimicrob Agents Chemother2011; 55: 4569–4574.
48.
PhamP.A., la PorteC.J.L., LeeL.S.Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers. Antimicrob Agents Chemother2009; 53: 4385–4392.
49.
MaltaisF., JungY.C., ChenM.In vitro and in vivo isotope effects with hepatitis C protease inhibitors: enhanced plasma exposure of deuterated telaprevir versus telaprevir in rats. J Med Chem2009; 52: 7993–8001.
50.
van HeeswijkR., BoogaertsG., De PaepeE.The pharmacokinetic (PK) interaction between esomeprazole and the investigational HCV protease inhibitor telaprevir. Rev in Antiviral Ther and Inf Dis2010; 5: 12.
51.
RaoN.The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet2007; 46: 281–290.
52.
van HeeswijkR., BoogaertsG., De PaepeE.The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir.5th International Workshop on Clinical Pharmacology of HCV Therapy. 23–24 June 2010, Boston, MA, USA. Abstract 12.
53.
GutierrezM., AbramowitzW.Lack of effect of a single dose of ketoconazole on the pharmacokinetics of citalopram. Pharmacotherapy2001; 21: 163–168.
54.
GutierrezM.M., RosenbergJ., AbramowitzW.An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Clin Ther2003; 25: 1200–1210.
55.
JageJ.Methadone: pharmacokinetics and pharmacodynamics of an opiate. Anaesthesist1989; 38: 159–166.
56.
EapC.B., BourquinM., MartinJ.Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. Drug Alcohol Depend2000; 61: 47–54.
KharaschE.D., BedynekP.S., ParkS.Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance. Clin Pharmacol Ther2008; 84: 497–505.
59.
van HeeswijkR., van de voordeA., VerbovenP.The pharmacokinetic interaction between methadone and the investigational HCV protease inhibitor telaprevir (TVR). J Hepatol2011; 54Suppl 1: S491–S492.
60.
BenetL.Z., HoenerB.A.Changes in plasma proteins have little clinical relevance. Clin Pharmacol Ther2002; 71: 115–121.
61.
LuoX., TrajevoJ., van HeeswijkR., GargV.No significant effect of the HCV protease inhibitor telaprevir on the pharmacokinetics and pharmacodynamics of buprenorphine in HCV-negative volunteers.HepDART 2011. 4–8 December 2011, Koloa, HI, USA. Abstract 132.
62.
LiC., LiuT., BroskeL.Permeability evaluation of peptidic HCV protease inhibitors in Caco-2 cells-correlation with in vivo absorption predicted in humans. Biochem Pharmacol2008; 76: 1757–1764.
63.
SchmittC., KaeserB., RiekM.Effect of saquinavir/ ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe. Int J Clin Pharmacol Ther2010; 48: 192–199.
64.
DingR., TayrouzY., RiedelK.D.Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther2004; 76: 73–84.
65.
FennerK.S., TroutmanM.D., KempshallS.Drug–drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther2009; 85: 173–181.
66.
WyenC., FuhrU., FrankD.Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CAP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clin Pharmacol Ther2008; 84: 75–82.
67.
GargV., van HeeswijkR., LeeJ.E., AlvesK., NadkarniP., LuoX.Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology2011; 54: 20–27.
68.
FrassettoL.A., BrowneM., ChengA.Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant2007; 7: 2816–2820.
69.
TeicherE., VincentI., Bonhomme-FaivreL.Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC 08 study. Clin Pharmacokinet2007; 46: 941–952.
70.
GargV., van HeeswijkR., YangY., KauffmanR., SmithF., AddaN.The pharmacokinetic interaction between an oral contraceptive containing ethinyl estradiol and norethindrone and the investigational HCV protease inhibitor telaprevir. J Clin Pharmacol2012; doi: 10.1177/0091270011419855.
